Translating scientific discoveries into affordable,
globally accessible public health solutions


What We Do


new approaches to developing vaccines and other means of preventing HIV.


translational and clinical research through our laboratories in the U.S., India, and the U.K.

Build Capacity

in-country for researching vaccine candidates while strengthening local public health and scientific expertise.


with industry and enlist biopharma product development skills to develop innovative products tailored to target populations.


IAVI’s resources with other innovators to help the HIV community as a whole succeed.


IAVI’s core capabilities to solving disease prevention and treatment challenges.

Latest News from IAVI

Black mamba

IAVI Partners in Snakebite Treatment Consortium

Partners in five countries will discover and develop monoclonal antibodies to treat critical illness from snake venom, which harms nearly 3 million people each year.

IAVI Report: Special issue on HIV vaccine science in Africa, for Africa

The issue was inspired by the elegant science being produced by scientists in Africa and the scientific capacity being built via IAVI’s ADVANCE program.

Donor Spotlight: U.S. Agency for International Development

IAVI recognizes USAID and the American people for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and biomedical prevention products for use throughout the world.

Vaccine being given in arm

Phase I Trial of Native-like HIV Env Trimer

Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein

Scientist in Lab

Need for TB Vaccine Research Support

World TB Day falls on March 24 each year. It marks the day in 1882 when Robert Koch announced that he had identified the cause of TB.

The Need for Long-Acting HIV Prevention

Women living in Kenya and South Africa describe the cultural and economic barriers to HIV prevention.



Kenya HIV & AIDS Research Agenda